Clinical Trial Update: 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of individualized dosimetry-based delivery of Lutathera (177Lu-DOTATATE) for neuroendocrine tumors, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: University of Iowa | Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 | Status: RECRUITING